Otsuka acquires all shares of DIATRANZ, develops encapsulated porcine islets

On January 25, Otsuka Pharmaceutical Factory acquired all remaining shares (50%) owned by New Zealand Living Cell Technologies (LCT), a company holding, in favor of its joint venture company DIATRANZ OTSUKA, which is engaged in the development of encapsulated porcine pancreatic islet cells "DIABECELL". DIABECELL are islets isolated from specific pathogen free (DPF) newborn pigs kept in isolation facilities. The islets are alginated and embedded in poly L-ornithine capsules.

Source: Otsuka news release, January 25, 2018

Request a quote for deeper information from

© 2018 Window to Japan - Bio 4 Business - Imprint